EA200800294A1 - Способы нейропротекции - Google Patents
Способы нейропротекцииInfo
- Publication number
- EA200800294A1 EA200800294A1 EA200800294A EA200800294A EA200800294A1 EA 200800294 A1 EA200800294 A1 EA 200800294A1 EA 200800294 A EA200800294 A EA 200800294A EA 200800294 A EA200800294 A EA 200800294A EA 200800294 A1 EA200800294 A1 EA 200800294A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- phenyl
- alkyl
- formula
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к способу нейропротекции, включающему введение субъекту, нуждающемуся в этом, терапевтически эффективного количества соединения, выбранного из группы, состоящей из формулы (I) и формулы (II), или его фармацевтически приемлемой соли, или сложного эфира, где фенил замещен в Х от одного до пяти атомами галогена, выбранными из группы, состоящей из фтора, хлора, брома и йода, a R, R, R, R, Rи Rнезависимо выбраны из группы, состоящей из водорода и С-С-алкила, где С-С-алкил необязательно замещен фенилом (где фенил необязательно замещен заместителями, независимо выбранными из группы, состоящей из галогена, С-С-алкила, C-С-алкоксигруппы, аминогруппы, нитрогруппы и цианогруппы).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69840305P | 2005-07-12 | 2005-07-12 | |
PCT/US2006/026291 WO2007008562A2 (en) | 2005-07-12 | 2006-07-07 | Carbamate compounds for use in treating neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200800294A1 true EA200800294A1 (ru) | 2008-06-30 |
Family
ID=37637734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200800294A EA200800294A1 (ru) | 2005-07-12 | 2006-07-07 | Способы нейропротекции |
Country Status (18)
Country | Link |
---|---|
US (2) | US20070021500A1 (ru) |
EP (1) | EP1917009A2 (ru) |
JP (1) | JP2009501224A (ru) |
KR (1) | KR20080031951A (ru) |
CN (1) | CN101287459A (ru) |
AR (1) | AR054551A1 (ru) |
AU (1) | AU2006269381A1 (ru) |
BR (1) | BRPI0613006A2 (ru) |
CA (1) | CA2615129A1 (ru) |
CR (1) | CR9721A (ru) |
EA (1) | EA200800294A1 (ru) |
EC (1) | ECSP088179A (ru) |
IL (1) | IL188729A0 (ru) |
NI (1) | NI200800008A (ru) |
NO (1) | NO20080738L (ru) |
TW (1) | TW200800158A (ru) |
WO (1) | WO2007008562A2 (ru) |
ZA (1) | ZA200801401B (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1928451B1 (en) * | 2005-07-26 | 2011-12-28 | SK Biopharmaceuticals Co., LTD | Methods for treating substance-related disorders |
US9050005B2 (en) | 2005-08-25 | 2015-06-09 | Synapse Biomedical, Inc. | Method and apparatus for transgastric neurostimulation |
EP1996284A2 (en) * | 2006-03-09 | 2008-12-03 | Synapse Biomedical, Inc. | Ventilatory assist system and method to improve respiratory function |
US20080097153A1 (en) * | 2006-08-24 | 2008-04-24 | Ignagni Anthony R | Method and apparatus for grasping an abdominal wall |
MX2009003755A (es) * | 2006-10-06 | 2009-07-10 | Janssen Pharmaceutica Nv | Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato. |
WO2008098001A2 (en) * | 2007-02-05 | 2008-08-14 | Synapse Biomedical, Inc. | Removable intramuscular electrode |
WO2008144578A1 (en) * | 2007-05-17 | 2008-11-27 | Synapse Biomedical, Inc. | Devices and methods for assessing motor point electromyogram as a biomarker |
US8428726B2 (en) | 2007-10-30 | 2013-04-23 | Synapse Biomedical, Inc. | Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system |
US8478412B2 (en) * | 2007-10-30 | 2013-07-02 | Synapse Biomedical, Inc. | Method of improving sleep disordered breathing |
JP5815552B2 (ja) | 2009-12-08 | 2015-11-17 | ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University | 眼疾患を治療する化合物および方法 |
US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
KR101418061B1 (ko) * | 2012-09-28 | 2014-07-10 | 한국과학기술연구원 | 성상교세포의 글루타메이트 방출 기작 |
EP2970111A4 (en) * | 2013-03-12 | 2017-01-18 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compound and a composition for preventing or treating a nerve gas-induced disease comprising the same |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
JP6807941B2 (ja) * | 2016-02-29 | 2021-01-06 | バイオ−ファーム ソリューションズ カンパニー リミテッド | スルファメート誘導体化合物、その製造方法および用途 |
US11471683B2 (en) | 2019-01-29 | 2022-10-18 | Synapse Biomedical, Inc. | Systems and methods for treating sleep apnea using neuromodulation |
WO2022045824A1 (en) * | 2020-08-31 | 2022-03-03 | Bio-Pharm Solutions Co., Ltd. | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
AU782759B2 (en) * | 1999-08-20 | 2005-08-25 | Ortho-Mcneil Pharmaceutical, Inc. | Composition comprising a tramadol material and an anticonvulsant drug |
CN1235579C (zh) * | 2001-02-27 | 2006-01-11 | 奥索-麦克尼尔药品公司 | 用于预防或治疗神经变性疾病的氨基甲酸酯化合物 |
RS51269B (sr) * | 2004-09-16 | 2010-12-31 | Janssen Pharmaceutica N.V. | Upotreba 2-fenil-1,2-etandiol-(di)karbamata za tretiranje epileptogeneze |
PE20070325A1 (es) * | 2005-06-29 | 2007-05-12 | Alza Corp | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
-
2006
- 2006-07-06 US US11/481,601 patent/US20070021500A1/en not_active Abandoned
- 2006-07-07 CA CA002615129A patent/CA2615129A1/en not_active Abandoned
- 2006-07-07 BR BRPI0613006-2A patent/BRPI0613006A2/pt not_active IP Right Cessation
- 2006-07-07 AU AU2006269381A patent/AU2006269381A1/en not_active Abandoned
- 2006-07-07 WO PCT/US2006/026291 patent/WO2007008562A2/en active Application Filing
- 2006-07-07 KR KR1020087003268A patent/KR20080031951A/ko not_active Application Discontinuation
- 2006-07-07 CN CNA2006800331046A patent/CN101287459A/zh active Pending
- 2006-07-07 EP EP06786448A patent/EP1917009A2/en not_active Withdrawn
- 2006-07-07 JP JP2008521436A patent/JP2009501224A/ja not_active Withdrawn
- 2006-07-07 EA EA200800294A patent/EA200800294A1/ru unknown
- 2006-07-11 TW TW095125161A patent/TW200800158A/zh unknown
- 2006-07-11 AR ARP060102977A patent/AR054551A1/es not_active Application Discontinuation
-
2008
- 2008-01-10 IL IL188729A patent/IL188729A0/en unknown
- 2008-01-11 NI NI200800008A patent/NI200800008A/es unknown
- 2008-02-11 ZA ZA200801401A patent/ZA200801401B/xx unknown
- 2008-02-11 CR CR9721A patent/CR9721A/es unknown
- 2008-02-11 NO NO20080738A patent/NO20080738L/no not_active Application Discontinuation
- 2008-02-12 EC EC2008008179A patent/ECSP088179A/es unknown
-
2009
- 2009-01-30 US US12/362,970 patent/US20090137652A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1917009A2 (en) | 2008-05-07 |
KR20080031951A (ko) | 2008-04-11 |
TW200800158A (en) | 2008-01-01 |
CN101287459A (zh) | 2008-10-15 |
AR054551A1 (es) | 2007-06-27 |
CR9721A (es) | 2008-11-24 |
NO20080738L (no) | 2008-04-10 |
IL188729A0 (en) | 2008-11-03 |
AU2006269381A1 (en) | 2007-01-18 |
US20090137652A1 (en) | 2009-05-28 |
ECSP088179A (es) | 2008-03-26 |
ZA200801401B (en) | 2009-08-26 |
US20070021500A1 (en) | 2007-01-25 |
WO2007008562A2 (en) | 2007-01-18 |
CA2615129A1 (en) | 2007-01-18 |
NI200800008A (es) | 2010-11-25 |
WO2007008562A3 (en) | 2007-08-16 |
JP2009501224A (ja) | 2009-01-15 |
BRPI0613006A2 (pt) | 2010-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200800294A1 (ru) | Способы нейропротекции | |
NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
EA200701536A1 (ru) | Способы контроля интервала qt | |
NO20080739L (no) | Fremgangsmater for behandling av Epileptogenese | |
NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
YU67703A (sh) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja | |
EA200700871A1 (ru) | Способы нейропротекции | |
IL157590A0 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
RS67603A (en) | Carbamate compounds for use in the treatment of pain | |
MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
CO6160292A2 (es) | Metodos de tratamiento de transtornos de comportamiento perturbador 877 | |
HK1063435A1 (en) | Carbamate compounds for use in preventing or treating neuropathic pain | |
TW200701978A (en) | Methods of treating epileptogenesis and epilepsy | |
CY1110672T1 (el) | Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης | |
MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders |